Lantheus receives FDA approval for PYLARIFY TruVu prostate cancer imaging agent
Tweet Send to a Friend
Lantheus Holdings (NASDAQ: LNTH) announced that the U.S. Food and Drug Administration has approved PYLARIFY TruVu (piflufolastat F 18) injection ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


